Skip to main content
رجوع
Watch Compare

Aspire Biopharma Holdings, Inc.

جودة البيانات: 100%
مُدرج أيضًا باسم ASBPW Nasdaq
ASBP
Nasdaq Manufacturing Chemicals
KWD 1.06
▼ KWD 0.14 (-11.67%)
القيمة السوقية: 6.03 M
السعر
KWD 1.20
القيمة السوقية
6.03 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—

Quick Summary

النقاط الرئيسية

Negative free cash flow of -4.92 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
N/A
ROICN/A
Net Margin-394725.06%
Op. Margin-312016.95%

الأمان

Debt / Equity
N/A
Current Ratio0.17
Interest Coverage-2.27

التقييم

PE (TTM)
-0.25
أعلى من متوسط القطاع (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -0.3 -1.5
P/B — 1.6
ROE % — -53.4
Net Margin % -394725.1 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 6,202.0 Net Income (TTM) -24.48 M
ROE N/A ROA -1443.21%
Gross Margin -1.87% Operating Margin -312016.95%
Net Margin -394725.06% Free Cash Flow (TTM) -4.92 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.17
Interest Coverage -2.27 Asset Turnover 0.00
Working Capital -11.46 M Tangible Book Value -11.47 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.25 Forward P/E N/A
P/B Ratio N/A P/S Ratio 972.10
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -81.66%
Market Cap 6.03 M Enterprise Value 6.03 M
Per Share
EPS (Diluted TTM) -16.38 Revenue / Share 0.00
FCF / Share -0.98 OCF / Share -0.98
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 20.11%
SBC-Adj. FCF -19.05 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue 6,202.0 — — —
Net Income -24.48 M -12.54 M 4.46 M 3.34 M
EPS (Diluted) -16.38 — — —
Gross Profit -116.0 — — —
Operating Income -19.35 M — — —
EBITDA — — — —
R&D Expenses 923,914.0 — — —
SG&A Expenses — — — —
D&A — — — —
Interest Expense 8.53 M 891,624.0 8,966.0 —
Income Tax 1,013.0 — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 1.31 M 6.71 M 19.98 M 300.18 M
Total Liabilities 7.69 M 15.62 M 403,328.0 11.12 M
Shareholders' Equity -6.38 M -15.57 M -322,105.0 -9.94 M
Total Debt — — — —
Cash & Equivalents — — — —
Current Assets 1.31 M 45,842.0 81,223.0 1.10 M
Current Liabilities 7.59 M 15.62 M 403,328.0 303,323.0